Mr. Tyler Robson reports

VALENS RECEIVES UPDATED HEALTH CANADA LICENSE, PERMITS B2B SALES

Valens Groworks Corp. received its updated standard processing and standard cultivation licence on Nov. 9, 2018. The updated licensing has been issued in accordance with Health Canada's Cannabis Act and Cannabis Regulations, which had previously been issued under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

Effective immediately, the company's wholly owned subsidiary, Valens Agritech Ltd., is authorized to sell cannabis and cannabis products in accordance with Subsection 11(5) and 17(5) of the Cannabis Regulations. This updated licence from Health Canada allows Valens to engage in business-to-business (B2B) sales with its strategic partners and other qualified licence holders under the Cannabis Act and Cannabis Regulations, including executing on extraction agreements already in place.

"This is an extremely important milestone for the company as we continue to strategically execute on our business plan to be the leading extraction service provider in the industry," said Tyler Robson, chief executive officer, Valens. "Having this new licence in hand, combined with our proprietary extraction capabilities, will allow us to create further value for our shareholders and strategic business partners."

About Valens Groworks Corp.

Valens Groworks is a research-driven, vertically integrated Canadian cannabis company focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification, as well as associated quality testing, with three wholly owned subsidiaries located in and around Kelowna, B.C. Subsidiary Valens Agritech (VAL) holds a standard processing and standard cultivation licence class under the Cannabis Act. Subsidiary Valens Labs is an ISO 17025-accredited cannabis testing lab, providing sector-leading analytical services, and has partnered with Thermo Fisher Scientific to develop a centre of excellence in plant-based science. Subsidiary Valens Farms is in the process of becoming a purpose-built facility in compliance with European Union (EU) good manufacturing practice (GMP) standards, ensuring the product from this facility can be exported anywhere in the world where cannabis is nationally legal for medical or adult usage purposes.

We seek Safe Harbor.